Cardiovascular complications of polychemotherapy of oncohematological diseases: Modern approaches to diagnostics
Heart dysfunction that occurred after using of cytostatic drugs and monoclonal antibodies may be a limit factor in treatment of oncohematological diseases. Side effects of chemotherapy include decline of quality of life, hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporozhye State Medical University
2012-12-01
|
| Series: | Zaporožskij Medicinskij Žurnal |
| Subjects: | |
| Online Access: | http://zmj.zsmu.edu.ua/article/view/18015/15762 |
| Summary: | Heart dysfunction that occurred after using of cytostatic drugs and monoclonal antibodies may be a limit factor in treatment of oncohematological diseases. Side effects of chemotherapy include decline of quality of life, hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect the cardiovascular toxicity before appearance of clinical signs of heart and vessel disturbance. The role of markers in elicitation of risk
group of cardiovascular events is uncertain yet. Early diagnostics and defi nition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solved problems. |
|---|---|
| ISSN: | 2306-4145 2310-1210 |